危重脓毒症患者的退热治疗:系统评价与Meta分析
该系统评价与Meta分析检索了截至2016年2月的多个数据库,纳入8项随机研究(1507例)和8项观察性研究(17432例)的成人脓毒症患者,评估退热治疗对死亡率等结局的影响。随机研究显示退热治疗未降低28天/住院死亡率(RR 0.93,95%CI 0.77-1.13;I²=0.0%),观察性研究结果类似(OR 0.90,95%CI 0.54-1.51;I²=76.1%)。休克逆转(RR 1.13,95%CI 0.68-1.90;I²=51.6%)和院内感染获得(RR 1.13,95%CI 0.61-2.09;I²=61.0%)均无显著变化。退热治疗降低了体温(平均差-0.38°C,95%CI -0.63至-0.13;I²=84.0%),但未降低心率或分钟通气量。结论认为退热治疗未显著改善成人脓毒症患者的28天/住院死亡率。
要点
- 在成人脓毒症患者中,退热治疗未显著降低28天/住院死亡率:随机研究RR 0.93(95%CI 0.77-1.13;I²=0.0%),观察性研究OR 0.90(95%CI 0.54-1.51;I²=76.1%)。
- 退热治疗未显著改变休克逆转(RR 1.13,95%CI 0.68-1.90;I²=51.6%)或院内感染获得(RR 1.13,95%CI 0.61-2.09;I²=61.0%)。
- 退热治疗可降低体温(平均差-0.38°C,95%CI -0.63至-0.13;I²=84.0%),但未显著降低心率或分钟通气量。
- 该Meta分析纳入8项随机研究(1507例)和8项观察性研究(17432例),随机与观察性研究分别分析。
- 纳入标准为观察性或随机研究、脓毒症患者、评估退热治疗、报告死亡率、有英文版本;排除儿科患者、神经损伤患者或健康志愿者。
适用人群与场景
- 成人脓毒症患者,纳入观察性或随机研究,要求评估退热治疗并报告死亡率。
- 排除儿科患者、神经损伤患者或健康志愿者。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,检索Ovid Medline、Embase、Scopus、CINAHL、Cochrane Central Register of Controlled Trials、NHS Economic Evaluation Database及ClinicalTrials.gov,截至2016年2月。
- 纳入8项随机研究(1507例)和8项观察性研究(17432例),随机与观察性研究分别分析。
- 主要终点:28天/住院死亡率,随机研究RR 0.93(95%CI 0.77-1.13;I²=0.0%),观察性研究OR 0.90(95%CI 0.54-1.51;I²=76.1%),均无显著差异。
- 次要终点:休克逆转RR 1.13(95%CI 0.68-1.90;I²=51.6%),院内感染获得RR 1.13(95%CI 0.61-2.09;I²=61.0%),均无显著差异。
- 体温变化:平均差-0.38°C(95%CI -0.63至-0.13;I²=84.0%),退热治疗组体温降低。
- 心率及分钟通气量无显著变化。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照研究和观察性研究,随机与观察性研究分别分析。
- 异质性:死亡率随机研究I²=0.0%,观察性研究I²=76.1%;休克逆转I²=51.6%;院内感染I²=61.0%;体温I²=84.0%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于成人脓毒症患者,该Meta分析显示退热治疗未显著降低28天/住院死亡率,未显著改变休克逆转或院内感染获得,但可降低体温(平均差-0.38°C)。
- 作者结论认为退热治疗未显著改善成人脓毒症患者的28天/住院死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This meta-analysis aimed to examine the impact of antipyretic therapy on mortality in critically ill septic adults.
DATA SOURCES: Literature searches were implemented in Ovid Medline, Embase, Scopus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov through February 2016.
STUDY SELECTION: Inclusion criteria were observational or randomized studies of septic patients, evaluation of antipyretic treatment, mortality reported, and English-language version available. Studies were excluded if they enrolled pediatric patients, patients with neurologic injury, or healthy volunteers. Criteria were applied by two independent reviewers.
DATA EXTRACTION: Two reviewers independently extracted data and evaluated methodologic quality. Outcomes included mortality, frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature, heart rate, and minute ventilation. Randomized and observational studies were analyzed separately.
DATA SYNTHESIS: Eight randomized studies (1,507 patients) and eight observational studies (17,432 patients) were analyzed. Antipyretic therapy did not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93; 95% CI, 0.77-1.13; I = 0.0%) or observational studies (odds ratio, 0.90; 95% CI, 0.54-1.51; I = 76.1%). Shock reversal (relative risk, 1.13; 95% CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61-2.09; I = 61.0%) were also unchanged. Antipyretic therapy decreased body temperature (mean difference, -0.38°C; 95% CI, -0.63 to -0.13; I = 84.0%), but not heart rate or minute ventilation.
CONCLUSIONS: Antipyretic treatment does not significantly improve 28-day/hospital mortality in adult patients with sepsis.
参考来源
- Drewry AM, Ablordeppey EA, Murray ET, et al. Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis. Crit Care Med. 2017. PMID: 28221185. doi:10.1097/CCM.0000000000002285
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。